|
37 Companies |
|
62 Products |
|
62 Products |
|
62 Mechanisms of Action |
|
5 Trials |
|
685 News |
|
| «12...234567891011121314» |
- ||||| apararenone (MT-3995) / Mitsubishi Tanabe
New P2 trial: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR (clinicaltrials.gov) - Dec 25, 2012
P2, N=90, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||||| apararenone (MT-3995) / Mitsubishi Tanabe
New P2 trial: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria (clinicaltrials.gov) - Dec 25, 2012
P2, N=90, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Tekturna (aliskiren) / PDL
Biomarker, Trial termination: ARIA: To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (clinicaltrials.gov) - Dec 20, 2012
P2, N=8, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; In consequence of termination of ALTITUDE. A number of studies were continued in consultation with the Altitude Data Monitoring Committee.
- Tekturna (aliskiren) / PDL
Biomarker, Enrollment change: ARIA: To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (clinicaltrials.gov) - Dec 20, 2012
P2, N=8, Terminated, Sponsor: Novartis Pharmaceuticals
A number of studies were continued in consultation with the Altitude Data Monitoring Committee. N=32 --> 8
- Trial completion: Computerized-Adaptive Testing: Feasibility In Women With Pelvic Floor Disorders (CAT) (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=20, Completed, Sponsor: Women and Infants Hospital of Rhode Island
N=32 --> 8 Active, not recruiting --> Completed
- ||| Enrollment open: CAPTURE: Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices (clinicaltrials.gov) - Dec 17, 2012
P=N/A, N=5000, Recruiting, Sponsor: American Medical Systems
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Urethral Length and TOT (Transobturator Tape) Positioning (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=123, Completed, Sponsor: Cantonal Hospital, Frauenfeld
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- || tamsulosin / Generic mfg.
New P3 trial: Tamsulosin for Urinary Retention in Hospitalized Older Women (clinicaltrials.gov) - Dec 10, 2012
P3, N=448, Recruiting, Sponsor: Assistance Publique - H
- || New P3 trial: HIM-UP: Health Interventions in Men Undergoing Radical Prostatectomy (clinicaltrials.gov) - Dec 10, 2012
P3, N=125, Recruiting, Sponsor: Johns Hopkins University
- Trial completion: Retropubic vs. Transobturator Tension-free Vaginal Tape (clinicaltrials.gov) - Dec 8, 2012
P=N/A, N=564, Completed, Sponsor: Austrian Urogynecology Working Group (AUWG)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Treatment for Female Stress Urinary Incontinence (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=168, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Vesicare (solifenacin) / Astellas
Enrollment change: Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease (clinicaltrials.gov) - Nov 29, 2012
P4, N=0, Withdrawn, Sponsor: University of South Florida
Recruiting --> Completed N=30 --> 0
- New P4 trial: Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose (clinicaltrials.gov) - Nov 28, 2012
P4, N=32, Completed, Sponsor: Gulhane School of Medicine
- tolterodine / Generic mfg.
Trial completion, HEOR, Cost effectiveness: UUI: The Long Term Outcomes of Rehabilitation and Drug Treatment for in Urgency Urinary Incontinence (clinicaltrials.gov) - Nov 27, 2012
P=N/A, N=164, Completed, Sponsor: Assuta Hospital Systems
N=30 --> 0 Active, not recruiting --> Completed
- Enrollment open: Psychometric Validation of a French Version of the PISQ-R and a New Questionnaire About Sexuality (clinicaltrials.gov) - Nov 25, 2012
P=N/A, N=300, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: BALLANCE: Periurethral Pro-ACTTM Balloons vs Retrourethral AdvanceXP(TM) Male Sling for Post-prostatectomy Incontinence (clinicaltrials.gov) - Nov 15, 2012
P=N/A, N=240, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| New P3 trial, HEOR: AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up (clinicaltrials.gov) - Nov 12, 2012
P3, N=100, Enrolling by invitation, Sponsor: American Medical Systems
- Enrollment open, HEOR: Urology Database to Evaluate Clinical Information and Improve Patient Care. (clinicaltrials.gov) - Nov 8, 2012
P=N/A, N=1000, Enrolling by invitation, Sponsor: Kenneth Peters, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Enrolling by invitation
- || New P2/3 trial: Vaginal DHEA for Women After Breast Cancer (clinicaltrials.gov) - Nov 7, 2012
P2/3, N=60, Not yet recruiting, Sponsor: Hadassah Medical Organization
- Tekturna (aliskiren) / PDL
Trial termination: Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients (clinicaltrials.gov) - Nov 5, 2012
P4, N=2, Terminated, Sponsor: John H. Stroger Hospital
Active, not recruiting --> Enrolling by invitation Suspended --> Terminated; Altitude trial which used similar drugs was terminated due to increased ADR.
- Tekturna (aliskiren) / PDL
Enrollment change: Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients (clinicaltrials.gov) - Nov 5, 2012
P4, N=2, Terminated, Sponsor: John H. Stroger Hospital
Suspended --> Terminated; Altitude trial which used similar drugs was terminated due to increased ADR. N=30 --> 2
- Trial withdrawal: Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Nov 4, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Virginia
N=30 --> 2 Recruiting --> Withdrawn
- Enrollment change: Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Nov 4, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Virginia
Recruiting --> Withdrawn N=28 --> 0
- |||| Vanrafia (atrasentan) / Novartis
Trial completion: Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (clinicaltrials.gov) - Oct 24, 2012
P2, N=149, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=28 --> 0 Active, not recruiting --> Completed
- | ramipril / Generic mfg.
New P4 trial: FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients (clinicaltrials.gov) - Oct 8, 2012
P4, N=78, Completed, Sponsor: Gulhane School of Medicine
- Trial initiation date: Evaluating the Necessity of TOT Implantation in Women With Pelvic Organ Prolapse and Occult Stress Urinary Incontinence (clinicaltrials.gov) - Oct 6, 2012
P=N/A, N=88, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Initiation date: Apr 2010 --> Sep 2010
- Enrollment change: TVTSOffice: TVT-SECUR as an Office-based Procedure (clinicaltrials.gov) - Oct 4, 2012
P=N/A, N=50, Completed, Sponsor: Michigan Institution of Women's Health PC
Initiation date: Apr 2010 --> Sep 2010 N=20 --> 50
- | Trial completion: TVTSOffice: TVT-SECUR as an Office-based Procedure (clinicaltrials.gov) - Oct 4, 2012
P=N/A, N=50, Completed, Sponsor: Michigan Institution of Women's Health PC
N=20 --> 50 Active, not recruiting --> Completed
- | New P4 trial: Multicentric Comparative Randomized Study of the Single-incision Sling Ajust (clinicaltrials.gov) - Oct 1, 2012
P4, N=140, Recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- || paricalcitol / Generic mfg.
New P3 trial: Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria (clinicaltrials.gov) - Sep 25, 2012
P3, N=70, Not yet recruiting, Sponsor: Oslo University Hospital
- Trial termination: Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT) (clinicaltrials.gov) - Sep 19, 2012
P3, N=74, Terminated, Sponsor: University of Calgary
Active, not recruiting --> Completed Active, not recruiting --> Terminated; poor recruitment
- Enrollment change: Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT) (clinicaltrials.gov) - Sep 19, 2012
P3, N=74, Terminated, Sponsor: University of Calgary
Active, not recruiting --> Terminated; poor recruitment N=300 --> 74
- Trial completion: Self Management in Urinary Catheter Users (clinicaltrials.gov) - Sep 16, 2012
P2, N=202, Completed, Sponsor: University of Rochester
N=300 --> 74 Active, not recruiting --> Completed
- | Trial initiation date: BETTUR PD: Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov) - Sep 12, 2012
P3, N=60, Recruiting, Sponsor: Atlanta VA Medical Center
Active, not recruiting --> Completed Initiation date: Mar 2012 --> Sep 2012
- | Enrollment open: BETTUR PD: Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov) - Sep 12, 2012
P3, N=60, Recruiting, Sponsor: Atlanta VA Medical Center
Initiation date: Mar 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- |||| Vanrafia (atrasentan) / Novartis
Trial completion: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan (clinicaltrials.gov) - Sep 11, 2012
P2, N=58, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion, HEOR: I-STOP TOMS - Trans Obturator Male Sling (clinicaltrials.gov) - Sep 7, 2012
P4, N=50, Completed, Sponsor: CL Medical
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| paricalcitol / Generic mfg.
Trial initiation date: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 4, 2012
P3, N=166, Recruiting, Sponsor: University Medical Centre Ljubljana
Recruiting --> Completed Initiation date: Dec 2011 --> Jul 2012
- |||||| paricalcitol / Generic mfg.
Enrollment open: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 4, 2012
P3, N=166, Recruiting, Sponsor: University Medical Centre Ljubljana
Initiation date: Dec 2011 --> Jul 2012 Not yet recruiting --> Recruiting
- aspirin / Generic mfg.
Trial completion: Aspirin and the Risk of Microscopic Hematuria in Asymptomatic Screened Population (clinicaltrials.gov) - Aug 26, 2012
P=N/A, N=60048, Completed, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Trial termination, HEOR: Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP (clinicaltrials.gov) - Aug 21, 2012
P=N/A, N=21, Terminated, Sponsor: pfm medical ag
Not yet recruiting --> Completed Recruiting --> Terminated; major recruitment failure
- Enrollment change, HEOR: Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP (clinicaltrials.gov) - Aug 21, 2012
P=N/A, N=21, Terminated, Sponsor: pfm medical ag
Recruiting --> Terminated; major recruitment failure N=240 --> 21
- ||| Enrollment change: Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence (clinicaltrials.gov) - Aug 20, 2012
P4, N=132, Completed, Sponsor: Barrie Urology Associates
N=240 --> 21 N=200 --> 132
- |||| Trial completion: Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence (clinicaltrials.gov) - Aug 20, 2012
P4, N=132, Completed, Sponsor: Barrie Urology Associates
N=200 --> 132 Active, not recruiting --> Completed
- Enrollment change: BLISS: Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study (clinicaltrials.gov) - Aug 15, 2012
P2, N=70, Recruiting, Sponsor: Austin Health
Active, not recruiting --> Completed N=170 --> 70
- ||||||| Trial completion: The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence (clinicaltrials.gov) - Aug 15, 2012
P3, N=166, Completed, Sponsor: Solace Therapeutics, Inc.
N=170 --> 70 Active, not recruiting --> Completed
- Enrollment change: A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy (clinicaltrials.gov) - Aug 12, 2012
P=N/A, N=20, Completed, Sponsor: ThermaRx, Inc.
Active, not recruiting --> Completed N=60 --> 20
- | Trial completion: A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy (clinicaltrials.gov) - Aug 12, 2012
P=N/A, N=20, Completed, Sponsor: ThermaRx, Inc.
N=60 --> 20 Recruiting --> Completed
- Trial completion: Validation of a New Sexuality Questionnaire for Patients With Urinary Incontinence or Pelvic Organ Prolapse (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=25, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Validation of a French Version of the PISQ-R (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=25, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Completed Not yet recruiting --> Completed